260 related articles for article (PubMed ID: 27567832)
1. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
van Steenoven I; Aarsland D; Weintraub D; Londos E; Blanc F; van der Flier WM; Teunissen CE; Mollenhauer B; Fladby T; Kramberger MG; Bonanni L; Lemstra AW;
J Alzheimers Dis; 2016 Aug; 54(1):287-95. PubMed ID: 27567832
[TBL] [Abstract][Full Text] [Related]
2. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
4. Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias.
Geng C; Tan L; Chen C
Brain Res; 2024 Jun; 1833():148881. PubMed ID: 38519009
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
[TBL] [Abstract][Full Text] [Related]
6. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D
J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia.
Gmitterová K; Gawinecka J; Llorens F; Varges D; Valkovič P; Zerr I
Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):461-470. PubMed ID: 30083957
[TBL] [Abstract][Full Text] [Related]
9. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
[TBL] [Abstract][Full Text] [Related]
11. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
[TBL] [Abstract][Full Text] [Related]
12. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies.
Lemstra AW; de Beer MH; Teunissen CE; Schreuder C; Scheltens P; van der Flier WM; Sikkes SA
J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):113-118. PubMed ID: 27794030
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
[TBL] [Abstract][Full Text] [Related]
14. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
[TBL] [Abstract][Full Text] [Related]
15. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
Shea YF; Ha J; Chu LW
Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
[TBL] [Abstract][Full Text] [Related]
17. Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias.
Howard E; Irwin DJ; Rascovsky K; Nevler N; Shellikeri S; Tropea TF; Spindler M; Deik A; Chen-Plotkin A; Siderowf A; Dahodwala N; Weintraub D; Shaw LM; Trojanowski JQ; Vaishnavi SN; Wolk DA; Mechanic-Hamilton D; Morley JF; Duda JE; Grossman M; Cousins KAQ
Neurology; 2021 Apr; 96(14):e1855-e1864. PubMed ID: 33593865
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage.
Bousiges O; Bombois S; Schraen S; Wallon D; Quillard MM; Gabelle A; Lehmann S; Paquet C; Amar-Bouaziz E; Magnin E; Miguet-Alfonsi C; Delbeuck X; Lavaux T; Anthony P; Philippi N; Blanc F;
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):467-475. PubMed ID: 29321140
[TBL] [Abstract][Full Text] [Related]
19. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
Vranová HP; Hényková E; Kaiserová M; Menšíková K; Vaštík M; Mareš J; Hluštík P; Zapletalová J; Strnad M; Stejskal D; Kaňovský P
J Neurol Sci; 2014 Aug; 343(1-2):120-4. PubMed ID: 24928081
[TBL] [Abstract][Full Text] [Related]
20. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
